Overview of the needs and realities for developing new and improved vaccines in the 21st century

Intervirology

Volumn 45, Issue 4-6, 2002, Pages 199-211

  Hilleman, Maurice R ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

New and improved vaccines; Vaccine technology; Vaccines; Vaccines for the 2000s

Indexed keywords

ANTHRAX VACCINE; ANTIGEN; BACTERIAL VACCINE; BCG VACCINE; BOTULINUM TOXIN A; CHICKENPOX VACCINE; CHOLERA VACCINE; DIPHTHERIA VACCINE; DNA VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; LYME DISEASE VACCINE; MEASLES VACCINE; MENINGOCOCCUS VACCINE; MUMPS VACCINE; PARAINFLUENZA VACCINE; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; POLYSACCHARIDE; RABIES VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; ROTAVIRUS VACCINE; RUBELLA VACCINE; TETANUS TOXOID; TYPHOID VACCINE; UNINDEXED DRUG; VIRUS VACCINE; YELLOW FEVER VACCINE;

ALZHEIMER DISEASE; AMYLOIDOSIS; BACTERIAL INFECTION; BOVINE SPONGIFORM ENCEPHALOPATHY; CANCER IMMUNIZATION; CONFERENCE PAPER; DRUG TARGETING; GOVERNMENT; HUMAN; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; RESPONSIBILITY; VACCINATION; VIRUS INFECTION;

AMYLOIDOSIS; ANIMALS; CANCER VACCINES; HUMANS; VACCINES;

BACTERIA (MICROORGANISMS);

EID: 0036983181     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000067911     Document Type: Conference Paper

References (90)

1. Jenner E: An Inquiry into the Causes and Effects of the Variolae Vaccine. London, Lowe, 1798.
2. Plotkin SL, Plotkin SA: A short history of vaccination; in Plotkin SA, Orenstein WA (eds): Vaccine. Philadelphia, Saunders, 1999, pp 1-12.
3. Hilleman MR: Vaccines in historic evolution and perspective: A narrative of vaccine discoveries. Vaccine 2000;18:1436-1447.
4. Hilleman MR: Personal historical chronicle of six decades of basic and applied research in virology, immunology, and vaccinology. Immunol Rev 1999;170:7-27.
5. Hilleman MR: Overview of vaccinology in historic and future perspective: The whence and whither of a dynamic science with complex dimensions; Ertl H (ed): DNA Vaccines. Georgetown, Landes Bioscience, in press (present access: Eurekah.com, http://www.eurekah.com/reports/vaccines/ertl/10/ertl10.html).
6. Heilman C, McInnes P, Gerber MA: Accelerated Development of Vaccines. The Jordan Report 2000. Bethesda, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 2000.
7. Institute of Medicine, Committee to Study Priorities for Vaccine Development: New Vaccine Development: Establishing Priorities. Washington, National Academy, 1985, vol 1: Diseases of Importance in the United States.
8. Institute of Medicine, Committee to Study Priorities for Vaccine Development; Stratton KR, Durch JS, Lawrence RS (eds): Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, National Academy, 2000.
9. Basch PF: Vaccines and Public Health. Science, Policy and Practice. New York, Oxford University Press, 1994.
10. Mahoney RT, Maynard JE: The introduction of new vaccines into developing countries. Vaccine 1999;17:646-652.
11. Bellamy C: The State of the World's Children, 2000. New York, United Nations Children's Fund (UNICEF), 2000.
12. World Health Organization: World Health Report 2000. Health Systems: Improving Performance. Geneva, World Health Organization, 2000.
13. Nossal GJV: The Global Alliance for Vaccines and Immunization - a millennial challenge. Nat Immunol 2000;1:5-8.
14. Sachs J: Helping the world's poorest. Economist 1999;352:17-20.
15. Bloom BR, Widdus R: Vaccine visions and their global impact. Nat Med 1998;4(5 suppl):480-484.
16. Hilleman MR: Overview of vaccinology with special reference to papillomavirus vaccines. J Clin Virol 2000;19:79-90.
17. Chisari FV: Hepatitis B in transgenic mice: Insights into the virus and the disease. Hepatology 1995;22:1316-1325.
18. Guidotti LG, Chisari FV: Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001;19:65-91.
19. Hilleman MR: Overview of the pathogenesis, prophylaxis and therapeusis of viral hepatitis B, with focus on reduction to practical applications. Vaccine 2001;19:1837-1848.
20. Halsey NA: Increased mortality after high titer measles vaccines: Too much of a good thing. Pediatr Infect Dis J 1993;12:462-465.
21. Garenne M, Leroy O, Beau JP, Sene I: Child mortality after high-titre measles vaccines: Prospective study in Senegal. Lancet 1991;338:903-907.
22. Hilleman MR: Current overview of the pathogenesis and prophylaxis of measles with focus on practical implications. Vaccine 2001;20:651-665.
23. Fulginiti VA, Eller JJ, Downie AW, Kempe CH: Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles vaccines. JAMA 1967;202:1075-1080.
24. Polack FP, Auwaerter PG, Lee S-H, Nousari HC, Valsomakis A, Leiferman KM, Diwan A, Adams RJ, Griffin DE: Production of atypical measles in rhesus macaques: Evidence for disease mediated by immune complex formation and eosinophils in the presence of fusion-inhibiting antibody. Nat Med 1999;5:629-634.
25. Kapikian AZ, Mitchell RH, Chanock RM, Shuldoff RA, Stewart CE: An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969;89:405-421.
26. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrott RH: Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969;89:422-434.
27. McAdam KPWJ: Recent progress in bacterial vaccines: Tuberculosis. Int J Infect Dis 1997;1:172-178.
28. Fine PE: Variation in protection to BCG: Implications of and for heterologous immunity. Lancet 1995;346:1339-1345.
29. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, et al: Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998;393:537-544.
30. Behr MA, Wilson MA, Gill WP, Salamon H, Schoolnik GK, Rane S, Small PM: Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 1999;284:1520-1523.
31. Haynes BF, Pantaleo G, Fauci AS: Toward an understanding of the correlates of protective immunity to HIV infection. Science 1996;271:324-328.
32. Nabel G: Challenges and opportunities for development of an AIDS vaccine. Nature 2001;19:1002-1007.
33. Rousseau MC, Moreau J, Delmont J: Vaccination and HIV: A review of the literature. Vaccine 2000;18:825-831.
34. Hilleman MR: The frustrating journey toward an AIDS vaccine. Proc Am Philos Soc 2000;144:349-359.
35. Cohen J: AIDS vaccines show promise after years of frustration. Science 2001;291:1686-1688.
36. Hilleman MR: A simplified vaccinologist's vaccinology and the pursuit of a vaccine against AIDS. Vaccine 1998;16:778-793.
37. Miller LH, Hoffman SL: Research toward vaccines against malaria. Nat Med 1998;4(5 suppl):520-524.
38. Holder AA: Malaria vaccines. Proc Natl Acad Sci USA 1999;96:1167-1169.
39. Doolan DL, Hedstrom RC, Gardner MJ, Sedegah M, Wang H, Gramzinski RA, Margalith M, Hobart P, Hoffman SL: DNA vaccination as an approach to malaria control: Current status and strategies. Curr Top Microbiol Immunol 1998;226:37-56.
40. Le Scanf C, Fandeur T, Bonnefoy S, Guillotte M, Mercereau-Puijalon O: Novel targets of the variant-specific immune response to Plasmodium falciparum identified by differential screening of an expression library. Infect Immun 1999;67:64-73.
41. Chen C-H, Wu T-C: Experimental vaccine strategies for cancer immunotherapy. J Biomed Sci 1998;5:231-252.
42. Hipp JD, Hipp JA, Lyday BW, Minev BR: Cancer vaccines: An update. In Vivo 2000;14:571-585.
43. Rosenberg SA: Progress in human tumour immunology and immunotherapy. Nature 2001;411:380-384.
44. Zinkernagel RM: Immunity against solid tumors. Int J Cancer 2000;93:1-5.
45. Meidenbauer N, Andreesen R, Mackensen A: Dendritic cells for specific cancer immunotherapy. Biol Chem 2001;382:507-520.
46. Restifo NP: Cancer vaccines '98: A reductionistic approach. Bethesda, MD, USA, 27-28 April 1998. Mol Med Today 1998;4:327.
47. Struck M-M: Chances and risks of developing vaccines. Vaccines 1996;14:1301-1302.
48. Heck LW: The amyloid diseases; in Bennett JC, Plum F (eds): Cecil Textbook of Medicine. Philadelphia, Saunders, 1996, pp 1504-1506.
49. Kopito RR, Ron D: Conformational disease. Nat Cell Biol 2000;2:E207-E209.
50. Sipe JD, Cohen AS: Review: History of the amyloid fibril. J Struct Biol 2000;130:88-98.
51. Sadana A, Vo-Dinh T: Biomedical implications of protein folding and misfolding. Bioechnol Appl Biochem 2001;33:7-16.
52. Wickner RB, Edskes HK, Maddelein M-L, Taylor KL, Moriyama H: Prions of yeast and fungi. Proteins as genetic material. J Biol Chem 1999;274:555-558.
53. Kelly JW: Mechanisms of amyloidogenesis. Nat Struct Biol 2000;7:824-826.
54. Marx J: Neurobiology. New clue to the cause of Alzheimer's. Science 2001;292:1468.
55. Younkin SG: Amyloid β vaccination: Reduced plaques and improved cognition. Nat Med 2001;7:18-19.
56. Chen G, Chen KS, Knox J, Inglis J, Bernard A, Martin SJ, Justice A, McConlogue L, Games D, Freedman SB, Morris RG: A learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease. Nature 2000;408:975-979.
57. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW: A β peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000;408:982-985.
58. James C, Pearson J, McLaurin JA, Matthews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, St George-Hyslop P, Westaway D: A β peptide immunization reduces behavioral impairment and plaques in a model of Alzheimer's disease. Nature 2000;408:979-982.
59. Ironside JW: Prion diseases in man. J Pathol 1998;186:227-234.
60. Hope J: Prions and neurodegenerative diseases. Curr Opin Genet Dev 2000;10:568-574.
61. Aguzzi A: Prion diseases, blood and the immune system: Concerns and reality. Haematologica 2000;85:3-10.
62. Lee DH, Granja JR, Martinez JA, Severin K, Ghadiri MR: A self-replicating peptide. Nature 1996;382:525-528.
63. Brown P, Will RG, Bradley R, Asher D, Detwiler L: Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease: Background, evolution, and current concerns. Emerg Infect Dis 2001;7:6-16.
64. Aguzzi A, Montrasio F, Kaeser PS: Prions: Health scare and biological challenge. Nat Rev Mol Cell Biol 2001;2:118-126.
65. More than just mad cow disease (editorial). Nat Struct Biol 2001;8:281.
66. Balter M: Origins of BSE. Intriguing clues to a scrapie-mad cow link. Science 2001;292:827-829.
67. Hilleman MR: The business of science and the science of business in the quest for an AIDS vaccine. Vaccine 1999;17:1211-1222.
68. Gibbons M: Science's new social contract with society. Nature 1999;402(6761 suppl):C81-C84.
69. Hall ZW, Scott C: University-industry partnership. Science 2001;291:553.
70. Hilleman MR: Past, present and future of measles, mumps, and rubella vaccines. Pediatrics 1992;90:149-153.
71. Hilleman MR: The development of live attenuated mumps virus vaccine, its historic perspective and it's role in the evolution of combined measles-mumps-rubella; in Plotkin S, Fantini B (eds): Vaccinia, Vaccination and Vaccinology: Jenner, Pasteur, and Their Successors. Par-is, Elsevier, 1996, pp 283-292.
72. Hilleman MR: Combined measles, mumps, and rubella Vaccines; in Ellis RW (ed): Combination Vaccines: Development, Clinical Research, and Approval. Totowa, Humana, 1999, pp 197-211.
73. Hilleman MR: Plasma-derived hepatitis B vaccine - a breakthrough in preventive medicine; in Ellis RW (ed): Hepatitis B Vaccines in Clinical Practice. New York, Dekker, 1992, pp 17-39.
74. Hilleman MR: Immunology, vaccinology and pathogenesis of hepatitis B; in Koprowski H, Oldstone MBA (eds): Microbe Hunters, Then and Now. Bloomington, Medi-Ed, 1996, pp 221-234.
75. Hilleman MR: Three decades of hepatitis vaccinology in historic perspective. A paradigm of successful pursuits; in Plotkin S, Fantini B (eds): Vaccinia, Vaccination and Vaccinology: Jenner, Pasteur and Their Successors. Paris, Elsevier, 1996, pp 199-209.
76. Kauffman EB, Bublot M, Gettig RR, Limbach KJ, Pincus SE, Taylor J: Live viral vaccines; in Ellis RW (ed): New Vaccine Technologies. Georgetown, Landes Bioscience, 2001, pp 101-132.
77. Kochi SK, Killeen KP: Live attenuated bacterial vectors; in Ellis RW (ed): New Vaccine Technologies. Georgetown, Landes Bioscience, 2001, pp 172-185.
78. Donnelly J, Ulmer J, Shiver JW, Liu M: DNA vaccines. Annu Rev Immunol 1997;15:617-648.
79. van Regenmortel MH: Pitfalls of reductionism in the design of peptide-based vaccines. Vaccine 2001;19:2369-2374.
80. Walmsley AM, Arntzen CJ: Plant derived vaccines; in Ellis RW (ed): New Vaccine Technologies. Georgetown, Landes Bioscience, 2001, pp 263-273.
81. Glenn GM: Transcutaneous immunization; in Ellis RW (ed): New Vaccine Technologies. Georgetown, Landes Bioscience, 2001, pp 292-304.
82. Gellin B (ed): The Jordan Report 98. Bethesda, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 1998.
83. Suhrbier A: Multi-epitope DNA vaccines. Immunol Cell Biol 1997;75:402-408.
84. Tam JP: Recent advances in multiple antigen peptides. J Immunol Methods 1996;196:17-32.
85. Jackson DC, Fitzmaurice CJ, Brown LE, Zeng W: Preparation and properties of totally synthetic immunogens. Vaccine 2000;18:355-361.
86. Kieber-Emmons T, Luo P, Qiu J, Chang TY, Insug O, Blaszcyk-Thurin M, Steplewski Z: Vaccination with carbohydrate peptide mimotopes promotes anti-tumor responses. Nat Biotechnol 1999;17:660-665.
87. Moxon ER: Applications of molecular microbiology to vaccinology. Lancet 1997;350:1240-1244.
88. Banks RE, Dunn MJ, Hochstrasser DR, Sanchez J-C, Blackstock W, Pappin DJ: Proteom-ics: New perspectives, new biomedical opportunities. Lancet 2000;356:1749-1756.
89. Chakravarti DN, Fiske MJ, Fletcher LD, Zagursky RJ: Application of genomics and pro-teomics for identification of bacterial gene products as potential gene candidates. Vaccine 2001;19:601-612.
90. Malakoff D: The numbers. NIH prays for a soft landing after its doubling ride ends. Science 2001;292:1992-1995.